There has been a lot of buzz about this company the last couple of weeks. I'm in check it out for yourself.
Business Summary
IMPH provides the expertise to establish correct diagnosis, accurate prognosis, treatment determination and patient
follow-up info. focused exclusively on cancer. For the nine months ended 9/97, revenues rose 74% to $26.5 million. Net
income applicable to Common rose 98% to $2.4 million. Revenues reflect an increase in case volume resulting from
increased sales and marketing activities. Earnings also reflect lower salaries and related costs as a percentage of sales.
Here is a link for your own DD.
dailystocks.com
The float is only 3.2 million, rumor has it that big money is coming in. Target price 55 in 98.
SK |
